

DAFTAR PUSTAKA

- Adondis, J., Mongi, J., Tiwow, G.A. dan Palandi, R.R. (2019) ‘Studi Potensi Interaksi Obat Pada Pasien Gagal Jantung Di Instalasi Rawat Inap Rumah Sakit Advent Manado’, *Biofarmasetikal Tropis*, 2(2), pp. 124–135. doi: 10.55724/jbiofartrop.v2i2.125.
- Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M., and Palareti, G. (2012) ‘Oral Anticoagulant Therapy’, *Chest*, 141(2), pp. e44S-e88S. doi: 10.1378/chest.11-2292.
- Ahmad, A. (2015) ‘Evaluation of Potential Drug - Drug Interactions in General Medicine Ward of Teaching Hospital in Southern India’, *Journal Of Clinical And Diagnostic Research*. doi: 10.7860/JCDR/2015/11264.5608.
- Andrade, J. et al. (2014) ‘The Clinical Profile and Pathophysiology of Atrial Fibrillation: Relationships Among Clinical Features, Epidemiology, and Mechanisms’, *Circulation Research*, 114(9), pp. 1453–1468. doi: 10.1161/CIRCRESAHA.114.303211.
- Baxter, K. (2009), *Stockley’s Drug Interaction*, 8th Edition, Pharmaceutical Press, London.
- Braverman, S. (1988), ‘Sucralfate-Warfarin Interaction’, *Drug Intelligence and Clinical Pharmacy*, vol. 22, pp. 913.
- Capodanno, D. (2021) ‘Triple Therapy, Dual Therapy, and Modulation of Anticoagulation Intensity’, *JACC: Cardiovascular Interventions*, 14(7), pp. 781–784. doi: 10.1016/j.jcin.2021.02.039.
- Chung, M.K., Refaat, M., Shen, W.K., Kutuyifa, V., Cha, Y.M., Di Biase, L., Baranchuk, A., Lampert, R., Natale, A., Fisher, J., Lakkireddy, D.R. and ACC Electrophysiology Section Leadership Council. (2020) ‘Atrial Fibrillation’, *Journal of the American College of Cardiology*, 75(14), pp. 1689–1713. doi: 10.1016/j.jacc.2020.02.025.
- Derbalah, A., Duffull, S., Newall, F., Moynihan, K., and Al-Sallami, H. (2019) ‘Revisiting the Pharmacology of Unfractionated Heparin’, *Clinical Pharmacokinetics*. doi: 10.1007/s40262-019-00751-7.

- Di Minno, A., Frigerio, B., Spadarella, G., Ravani, A., Sansaro, D., Amato, M., Kitzmiller, J. P., Pepi, M., Tremoli, E., & Baldassarre, D. (2017) 'Old and new oral anticoagulants: Food, herbal medicines and drug interactions', *Blood Reviews*, 31(4), pp. 193–203. doi: 10.1016/j.blre.2017.02.001.
- Diksis, N., Melaku, T., Assefa, D., and Tesfaye, D. (2019) 'Potential drug–drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia', *SAGE Open Medicine*, 7, p. 205031211985735. doi: 10.1177/2050312119857353.
- Drugs.com [Internet] (2022). *Drugs Interactions Checker*. https://www.drugs.com/drug_interactions.html.
- Escolar, G., Diaz-Ricart, M., Arellano-Rodrigo, E., & Galán, A. M. (2014) 'The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism', *Expert Opinion on Drug Metabolism & Toxicology*, 10(3), pp. 445–458. doi: 10.1517/17425255.2014.882897.
- Fawzy, A. M. and Lip, G. Y. H. (2019) 'Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation', *Expert Opinion on Drug Metabolism & Toxicology*, 15(5), pp. 381–398. doi: 10.1080/17425255.2019.1604686.
- Furst, D.E., Ulrich, R.W., and Prakash, S. (2018) 'Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout' in B.G. Katzung (ed.). *Basic & Clinical Pharmacology*. Fourteenth edition. New York Chicago San Francisco Athens London Madrid Mexico City Milan New Delhi Singapore Sydney Toronto: McGraw-Hill Education (A Lange medical book), pp. 1170-1187.
- Gallego, P. et al. (2014) 'SAME-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation', *The American Journal of Medicine*, 127(11), pp. 1083–1088. doi: 10.1016/j.amjmed.2014.05.023.
- Hakim, Lukman. (2016) *Optimasi Dosis, Seri Penemuan Obat dan Farmasi Klinik*. Yogyakarta: Bursa Ilmu.
- Hasnain, H., Ali, H., Zafar, F., Sial, A.A., Hameed, K., Shareef, H., Mallick, N., Tariq, A. and Fatima, R. (2017) 'Drug-drug Interaction; Facts and

- Comparisons With National and International Bench Marks. A Threat More Than A Challenge For Patient Safety In Clinical and Economic Scenario', *The Professional Medical Journal*, 24(03), pp. 357–365. doi: 10.17957/TPMJ/17.3670.
- Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.A., Dilaveris, P.E., Fauchier, L., Filippatos, G., Kalman, J.M., La Meir, M., Lane, D.A., Lebeau, J.P., Lettino, M., Lip, G., Pinto, F.J., Thomas, G.N., Valgimigli, M., Van Gelder I.C., Van Putte, B.P. and Watkins, C.L (2021) '2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)', *European Heart Journal*, 42(5), pp. 373–498. doi: 10.1093/eurheartj/ehaa612.
- Horn, J. R. (2018) 'Important Drug Interactions & Their Mechanisms' in B.G. Katzung (ed.). *Basic & Clinical Pharmacology*. Fourteenth edition. New York Chicago San Francisco Athens London Madrid Mexico City Milan New Delhi Singapore Sydney Toronto: McGraw-Hill Education (A Lange medical book), pp. 1170-1187.
- Kenneth, R. M. (2018) 'Drug Used in the Treatment of Gastrointestinal Disease' in B.G. Katzung (ed.). *Basic & Clinical Pharmacology*. Fourteenth edition. New York Chicago San Francisco Athens London Madrid Mexico City Milan New Delhi Singapore Sydney Toronto: McGraw-Hill Education (A Lange medical book), pp. 1087-1119.
- Keogh, J. P. (1983) 'Occupational Lung Disease and Compensation', *Annals of Internal Medicine*, 98(4), p. 553. doi: 10.7326/0003-4819-98-4-553.
- Ko, D., Rahman, F., Schnabel, R.B., Yin, X., Benjamin, E.J., and Christophersen, I.E. (2016) 'Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis', *Nature Reviews Cardiology*, 13(6), pp. 321–332. doi: 10.1038/nrcardio.2016.45.
- Korucu, F.C., Senyigit, E., Kostek, O., Demircan, N.C., Erdogan, B., Uzunoglu, S. and Cicin, I. (2018) 'A retrospective study on potential drug interactions: A

- single center experience’, *Journal of Oncological Sciences*, 4(2), pp. 80–84. doi: 10.1016/j.jons.2018.06.001.
- Kvasnicka, T., Malikova, I., Zenahlikova, Z., Kettnerova, K., Brzezakova, R., Zima, T., Ulrych, J., Briza, J., Netuka, I., & Kvasnicka, J. (2017) ‘Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions’, *Current Drug Metabolism*, 18(7). doi: 10.2174/1389200218666170518165443.
- Leentjens, J., Peters, M., Esselink, A. C., Smulders, Y., & Kramers, C. (2017) ‘Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, Fondaparinux, or DOACs?: Initial anticoagulation in patients with pulmonary embolism’, *British Journal of Clinical Pharmacology*, 83(11), pp. 2356–2366. doi: 10.1111/bcp.13340.
- Lerchenfeldt, Sarah. (2020). *Pharmacology*. 7th edition. Philadelphia : Wolters Kluwer
- Lip, G. Y. H. (2020) ‘Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study)’, *The American Journal of Cardiology*, p. 7.
- Lippi, G., Sanchis-Gomar, F. and Cervellin, G. (2021) ‘Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge’, *International Journal of Stroke*, 16(2), pp. 217–221. doi: 10.1177/1747493019897870.
- Margulescu, A. D. and Mont, L. (2017) ‘Persistent atrial fibrillation vs paroxysmal atrial fibrillation: differences in management’, *Expert Review of Cardiovascular Therapy*, 15(8), pp. 601–618. doi: 10.1080/14779072.2017.1355237.
- Matsushima, N., Lee, F., Sato, T., Weiss, D., and Mendell, J. (2013) ‘Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects: Clinical Pharmacology in Drug Development’, *Clinical Pharmacology in Drug Development*, 2(4), pp. 358–366. doi: 10.1002/cpdd.53.

- Merck Manuals. [Internet] (2023).
<https://www.merckmanuals.com/professional/resourcespages/about-the-merck-manuals?ruleredirectid=460>
- Niu, J., Straubinger, R. M. and Mager, D. E. (2019) 'Pharmacodynamic Drug–Drug Interactions', *Clinical Pharmacology & Therapeutics*, 105(6), pp. 1395–1406. doi: 10.1002/cpt.1434.
- Obas, V. and Vasan, R. S. (2018) 'The aging heart', *Clinical Science*, 132(13), pp. 1367–1382. doi: 10.1042/CS20171156.
- Padfield, G.J., Steinberg, C., Swampillai, J., Qian, H., Connolly, S.J., Dorian, P., Green, M.S., Humphries, K.H., Klein, G.J., Sheldon, R., Talajic, M., and Kerr, C.R. (2017) 'Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation', *Heart Rhythm*, 14(6), pp. 801–807. doi: 10.1016/j.hrthm.2017.01.038.
- Parasrampur, D. A. and Truitt, K. E. (2016) 'Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa', *Clinical Pharmacokinetics*, 55(6), pp. 641–655. doi: 10.1007/s40262-015-0342-7.
- Parrish, R. H., Waller, B. and Gondalia, B. G. (1992) 'Sucralfate—Warfarin Interaction', *The Annals of Pharmacotherapy*, vol. 26, pp. 1015.
- Parulian, L., Listyanti, E., Hati, A.K., & Sunnah, I. (2019) 'Analisis Hubungan Polifarmasi Dan Interaksi Obat Pada Pasien Rawat Jalan Yang Mendapat Obat Hipertensi Di Rsp. Dr. Ario Wirawan Periode Januari-Maret 2019', *Indonesian Journal of Pharmacy and Natural Product*, 2(2). doi: 10.35473/ijpnp.v2i2.280.
- PERKI. (2019) *Pedoman Tata Laksana Fibrilasi Atrium Nonvalvular*. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
- Plitt, A. and Giugliano, R. P. (2014) 'Edoxaban: Review of Pharmacology and Key Phase I to III Clinical Trials', *Journal of Cardiovascular Pharmacology and Therapeutics*, 19(5), pp. 409–416. doi: 10.1177/1074248414523675.

- Rey, A. M. and Gums, J. G. (1991) 'Altered Absorption of Digoxin, Sustained-Release Quinidine, and Warfarin with Sucralfate Administration', *DICP*, 25(7–8), pp. 745–746. doi: 10.1177/106002809102500710.
- Sedlak, T. et al. (2012) 'Sex Hormones and the QT Interval: A Review', *Journal of Women's Health*, 21(9), pp. 933–941. doi: 10.1089/jwh.2011.3444.
- Siontis, K. C., Geske, J. B. and Gersh, B. J. (2015) 'Atrial Fibrillation Pathophysiology and Prognosis: Insights From Cardiovascular Imaging', *Circulation: Cardiovascular Imaging*, 8(6), p. e003020. doi: 10.1161/CIRCIMAGING.115.003020.
- Staerk, L., Sherer, J.A., Ko, D., Benjamin, E.J., and Helm, R.H. (2017) 'Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes', *Circulation Research*, 120(9), pp. 1501–1517. doi: 10.1161/CIRCRESAHA.117.309732.
- Szczuko, M. et al. (2021) 'The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review', *International Journal of Molecular Sciences*, 22(21), p. 11644. doi: 10.3390/ijms222111644.
- Takase, T. et al. (2018) 'Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery', *Journal of Pharmaceutical Health Care and Sciences*, 4(1), p. 13. doi: 10.1186/s40780-018-0110-6.
- Tilton, J.J., Sanoski, C. and Bauman, J.L. (2020) 'The Arrhythmias' in J.T. DiPiro, G.C. Yee, L.M. Posey, S.T. Haines, T.D. Nolin, V. Ellingrod (eds).
- Uptodate. (2023), *Lexi-Interact: Lexicomp Interaction Checker*. https://www.uptodate.com/drug-interactions/?source=responsive_home#di-druglist
- Vazquez S.R. (2018) 'Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions', *Hematology. American Society of Hematology, Education Program*, 2018(1), pp. 339–347.
- Villa Zapata, L. et al. (2020) 'Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis', *Thrombosis and Haemostasis*, 120(07), pp. 1066–1074. doi: 10.1055/s-0040-1710592

- Vinarov, Z., Abdallah, M., Agundez, J., Allegaert, K., Basit, A.W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B.T., Grimm, M., Keszthelyi, D., Koziolk, M., Madla, C.M., Matthys, C., McCoubrey, L.E., Mitra, A., Reppas, C., Stappaerts, J., Steenackers, N., Trevaskis, N.L., Vanuysel, T., Vertzoni, M., Weitschies, W., Wilson, C., and Augustijns, P. (2021) 'Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review', *European Journal of Pharmaceutical Sciences*, 162, p. 105812. doi: 10.1016/j.ejps.2021.105812.
- Watson, C. J. et al. (2022) 'Warfarin Overdose in an Adolescent Not Dependent on Anticoagulation: Reversal Strategy and Kinetics', *Journal of Medical Toxicology*, 18(4), pp. 334–339. doi: 10.1007/s13181-022-00907-1.
- Weitz, J.I. (2011) 'Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs' in Goodman & Gilman's (ed.). *The pharmacological basis of therapeutics*. 12th Edition. New York: McGraw-Hill Education, pp. 849-876.
- Westerman, S. and Wenger, N. (2019) 'Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes', *Current Cardiology Reviews*, 15(2), pp. 136–144. doi: 10.2174/1573403X15666181205110624.
- Wiffen, P. (ed.) (2017) *Oxford handbook of clinical pharmacy*. Third edition. Oxford; New York, NY: Oxford University Press (Oxford medical publications).
- Wijesurendra, R. S., & Casadei, B. (2019). Mechanisms of atrial fibrillation. *Heart (British Cardiac Society)*, 105(24), 1860–1867. <https://doi.org/10.1136/heartjnl-2018-314267>
- Yin, O. Q. P., Tetsuya, K. and Miller, R. (2014) 'Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation', *Eur J Clin Pharmacol*, p. 13.
- Zehnder, J.L. (2018) 'Drugs Used in Disorders of Coagulation' in B.G. Katzung (ed.). *Basic & Clinical Pharmacology*. 14th Edition. London: McGraw-Hill Education, pp. 608-625.

Zimetbaum, P. (2017) 'Atrial Fibrillation', *Annals of Internal Medicine*, 166(5), p. ITC33. doi: 10.7326/AITC201703070.

